Quest for Novel Cardiovascular Biomarkers by Proteomic Analysis
- 22 June 2005
- journal article
- review article
- Published by American Chemical Society (ACS) in Journal of Proteome Research
- Vol. 4 (4) , 1181-1191
- https://doi.org/10.1021/pr0500197
Abstract
Atherosclerosis, and the resulting coronary heart disease and stroke, is the most common cause of death in developed countries. Atherosclerosis is an inflammatory process that results in the development of complex lesions or plaques that protrude into the arterial lumen. Plaque rupture and thrombosis result in the acute clinical complications of myocardial infarction (MI) and stroke. Although certain risk factors (dyslipidemias, diabetes, hypertension) and humoral markers of plaque vulnerability (C-reactive protein, interleukin-6, 10 and 18, CD40L) have been identified, a highly sensitive and specific biomarker or protein profile, which could provide information on the stability/vulnerability of atherosclerotic lesions, remains to be identified. In this review, we report several proteomic approaches which have been applied to circulating or resident cells, atherosclerotic plaques or plasma, in the search for new proteins that could be used as cardiovascular biomarkers. First, an example using a differential proteomic approach (2-DE and MS) comparing the secretome from control mammary arteries and atherosclerotic plaques is displayed. Among the different proteins identified, we showed that low levels of HSP-27 could be a potential marker of atherosclerosis. Second, we have revised several studies performed in cells involved in the pathogenesis of atherosclerosis (foam cells and smooth muscle cells). Another approach consists of performing proteomic analysis on circulating cells or plasma, which will provide a global view of the whole body response to atherosclerotic aggression. Circulating cells can bear information reflecting directly an inflammatory or pro-coagulant state related to the pathology. As an illustration, we report that circulating monocytes and plasma in patients with acute coronary syndromes has disclosed that mature Cathepsin D is increased both in the plasma and monocytes of these patients. Finally, the problems of applying proteomic approach directly to plasma will be discussed. The purpose of this review is to provide the reader with an overview of different proteomic approaches that can be used to identify new biomarkers in vascular diseases. Keywords: atherosclerosis • HSP-27 • cathepsin D • cardiovascular biomarkersKeywords
This publication has 30 references indexed in Scilit:
- The proteome and secretome of human arterial smooth muscle cellsProteomics, 2005
- Two‐dimensional maps and databases of the human macrophage proteome and secretomeProteomics, 2004
- Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesionsBlood, 2004
- SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancerCurrent Opinion in Biotechnology, 2004
- F-actin Capping (CapZ) and Other Contractile Saphenous Vein Smooth Muscle Proteins Are Altered by Hemodynamic StressMolecular & Cellular Proteomics, 2004
- Altered mRNA expression in renal biopsy tissue from patients with IgA nephropathyKidney International, 2003
- Proteomic analysis of human vessels: Application to atherosclerotic plaquesProteomics, 2003
- The Human Plasma ProteomeMolecular & Cellular Proteomics, 2002
- Apoptosis in the vasculature: mechanisms and functional importanceBritish Journal of Pharmacology, 2000
- Human aortic intima protein composition during initial stages of atherogenesisAtherosclerosis, 1986